Officials tried to cover up lead poisoning in China that left hundreds of nursery-age children sick
The officials tampered with the blood tests of students who were poisoned at Peixin Kindergarten in Tianshui city, north-west China, authorities said in a report on Sunday.
City officials were also found to have accepted bribes from an investor in Peixin while overlooking food safety inspections across multiple pre-schools, the report said.
In a bizarre attempt to attract more kindergarten students, chefs at Peixin had used inedible paint to 'enhance the look' of its mealsm the report added.
A fortnight ago, investigators found 'abnormal' levels of lead in the blood of 235 children. Food samples were later found to contain lead 2,000 times in excess of the national safety limit.
Initially, eight people were detained for their involvement in producing the toxic date cakes and corn rolls.
The report confirmed that of the eight detained, six of them - including the kindergarten's principal, cooks, and an investor - have been arrested.
Ten other officials are set to face 'formal accounting procedures' while another 17 people are under disciplinary action.
Authorities in Tianshui revealed on July 8 that 235 children from the privately-owned kindergarten were being treated in hospital after eating the poisonous snacks.
The cake, served at breakfast, returned a reading of 1,052 milligrams of lead per kilogram and the roll, served at another meal, was found with 1,340 milligrams per kilogram.
The nationwide limit for lead in wheat and starch is 0.5 milligrams per kilogram, according to Chinese government records.
A parent told state-run Jimu News tabloid last week that children had been experiencing stomach pain and nausea, and that some of their teeth turned black.
On Sunday, 234 of them had been discharged.
The Gansu Provincial Centre for Disease Control and Prevention was ordered to test 267 students and staff at Peixin after some showed symptoms of lead poisoning earlier this month, but officials 'did not take the work seriously', the report stated.
The person in charge of the tests 'seriously violated operating procedures, which distorted the results', according to the report.
Sunday's report named several people under investigation and revealed the lead concentrations found in various food samples, among other details.
It also accused staff at the Tianshui No. 2 People's Hospital of 'serious dereliction of duty' and described the institution's management of the case as 'chaotic'.
Authorities in Tianshui have also announced that children suffering from lead poisoning can receive free treatment at designated hospitals and legal assistance will be made available to affected families.
Peixin will be temporarily managed by a state-owned kindergarten.
Food safety scandals were once common in China, where tainted milk formula made hundreds of thousands of babies ill in 2008 and was linked to six deaths.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
21 minutes ago
- Daily Mail
Global outbreak fears surge as virus in China prompts quarantines and thousands of new cases are reported
Chinese officials announced Covid-like quarantines in some cities as cases of chikungunya virus continue to increase. Over 7,000 cases of the mosquito-borne virus have been reported across the southern city of Foshan in the Guangdong province of the country. Patients in the city are forced to stay in hospitals where their beds are covered with mosquito nets for a week or until they test negative, if sooner. No deaths have yet been reported. At least 12 other cities in Guangdong have reported infections, with about 3,000 cases being reported over the past week, bringing the total to over 10,000 in the country. Those experiencing fevers, joint pain or rashes are being asked to visit the nearest hospital so they can be tested for the virus in the country. Additionally, officials had ordered travelers from Foshan to undergo a 14-day home quarantine, similar to Covid restrictions, but that has since been withdrawn. Hong Kong also reported its first chikungunya case this week involving a 12-year-old boy who developed a fever, rash and joint pain after traveling to Foshan in July. The chikungunya virus is primarily spread by the Aedes mosquito species, and nearly half a million became infected between 2004 and 2005, leading to a worldwide epidemic. Diana Rojas Alvarez, a medical officer at the WHO, said of the new cases: 'We are seeing history repeating itself,' referencing the 2004-2005 outbreak. Chikungunya infections are most common in Asia, Africa and South America, though more recently cases have also emerged across Europe and the US. The virus can cause symptoms like fever, joint pain and life-threatening complications related to the heart and brain. The infection does not spread from person to person through bodily contact or saliva and can only be transmitted through a bite from an infected mosquito. Given the sudden increase in cases in China, the CDC has issued a travel advisory for Americans traveling to the country, urging them to exercise 'increased caution' following the outbreak. The federal agency is also asking Americans to ensure they have received both vaccinations against chikungunya. In late 2023, the FDA approved a vaccine for chikungunya for people over the age of 18 who are at increased risk of exposure to the virus called IXCHIQ. Similarly, another vaccine that mimics the effects of chikungunya in the body to build immunity, called VIMKUNYA, was also licensed in February 2025 for use in those aged 12 and above. These are not routine vaccines and are recommended to those traveling to areas with outbreaks or elevated risk and laboratory workers with potential exposure to the chikungunya virus. Experts are also asking people to regularly use insect repellents and wear long-sleeve clothing to prevent mosquito bites this summer. The current global surge began in early 2025, with major outbreaks in the Indian Ocean islands of La Reunion, Mayotte and Mauritius. According to the European Center for Disease Prevention and Control, there have been about 240,000 Chikungunya virus cases and 90 related deaths in 16 countries since the beginning of 2025 as of August 4. The virus has also spread to Madagascar, Somalia, Kenya and India and is making its way to Europe. Case counts have also been increasing in Samoa, Tonga, French Polynesia, Fiji and Kiribati. As of August 5, the CDC reports there have been 46 cases of chikungunya infections in the US that were contracted while traveling to high-risk areas. No deaths have yet been reported. While it remains unclear where patients contracted the virus, the federal agency has issued an elevated risk of exposure notice for Brazil, Colombia, India, Mexico, Nigeria, Pakistan, Philippines and Thailand and now China. Approximately 200 cases of the virus were reported in 2024 in the US. There are no reports on deaths. According to the CDC, chikungunya was rarely identified in American travelers before 2006. However, between 2006 and 2013, nearly 30 people tested positive for the infection every year in the US. All were travelers visiting or returning to the US from affected areas in Asia, Africa, or the Indian Ocean. In 2014, 2,799 cases, out of which 12 were locally acquired, were reported in various US states, including Florida, Texas, Puerto Rico, and the Virgin Islands, marking the year as the highest ever. Though not fatal, chikungunya can cause a range of effects, which are primarily marked by a sudden onset of fever and severe joint pain, while other common symptoms include muscle pain, headache, nausea, fatigue and rashes. While the acute phase of the illness usually resolves within a week or two, the joint pain can persist for weeks, months or even years in some individuals. However, in some cases, infections can progress to severe dengue, which can cause potentially life-threatening complications such as internal bleeding and organ damage, and death. In extreme cases, eye, heart and neurological complications have also been reported in people suffering from a chikungunya infection. Newborns, adults aged 65 and older and people with certain health conditions are also at risk of developing Type 2 diabetes, heart disease and high blood pressure due to an infection. While the virus cannot be transmitted directly from person to person, people can become infected with chikungunya when mosquitoes feed on an infected person and then bite them. If a pregnant woman is infected around the time of delivery, the baby can also be infected at birth, which often results in severe disease in the baby. While there is no medication to treat a chikungunya infection, its symptoms can be managed by taking acetaminophen for pain and drinking lots of fluids.
Daily Mail
2 hours ago
- Daily Mail
New York outbreak of deadly lung disease spread by air conditioners grows... as cases triple and another is dead
Another person has died and 36 more have been sickened in a deadly lung disease outbreak that is sweeping New York City. The patients were diagnosed with Legionnaires' disease, a bacterial infection caught from breathing in water vapor that kills about one in 10 people it infects. The latest update brings the total number of deaths to two and cases to 58, and officials fear there are more patients in the city who are infected but undiagnosed. The New York City Health Department warned Monday: 'People living or working in the area with flu-like symptoms, such as cough, fever, chills, muscle aches, or difficulty breathing, should contact a healthcare provider immediately. 'It is especially important for people at higher risk, including those ages 50 and older, cigarette smokers, and people with chronic lung disease or compromised immune systems, to get care if they have symptoms.' All the cases have been detected in five ZIP codes covering the Harlem, East Harlem and Morningside Heights neighborhoods. It is not clear how patients were infected, but officials have said that 11 cooling towers in the area have tested positive for the bacteria that cause the disease. In previous cases, cooling towers have released water vapor contaminated with the bacteria; then, people walking outside the building have breathed it in, causing them to become infected. It is unlikely that the cooling towers infected people inside their buildings because the vapor is typically released outside. Legionnaires' disease can also be spread by air conditioning units if the bacteria contaminate water droplets within the system. Officials have said there is no contamination of municipal water supplies and it is still safe to drink tap water and to bathe, shower or use water for other purposes. The disease is not spread from person to person. No further details on the patients, including their names, ages, and how they were infected, have been released to date. The five ZIP codes affected in the outbreak are: 10027, 10030, 10035, 10037 and 10039. Acting Health Commissioner Dr Michelle Morse said: 'Anyone in these ZIP codes with flu-like symptoms should contact a healthcare provider as soon as possible. 'Legionnaires' disease can be effectively treated if diagnosed early, but New Yorkers at higher risk, like adults aged 50 and older and those who smoke or have chronic lung conditions, should be especially mindful of their symptoms and seek care as soon as symptoms begin.' Legionnaires' disease is caused by Legionella bacteria, which thrive in warm water and can become airborne if this is turned into steam. Infected patients initially suffer from a headache, muscle aches, and fever that may be 104 Fahrenheit (40 Celsius) or higher. But within three days, they may experience a cough, shortness of breath, chest pain, nausea, vomiting and diarrhea, and confusion or other mental changes. In serious cases, patients can develop severe pneumonia, and the bacteria can spread to the blood, causing the potentially fatal complication sepsis. The bacteria can also infect the heart. Patients die from the disease due to lung failure, septic shock, a sudden severe drop in blood flow to vital organs, or acute kidney failure, when these organs stop filtering waste from the blood. Doctors treat the disease using antibiotics, but say these are most effective in the early stages before the disease has spread in the body. Patients are often hospitalized. In milder cases, patients may also suffer from Pontiac fever, a condition causing fever, chills, headache and muscle aches that occurs when the bacteria do not infect the lungs. This condition goes away on its own without treatment and causes no further problems, doctors say. The New York City outbreak was first revealed on July 22, when the health department reported eight cases. All buildings that had units that tested positive for the Legionella bacteria were told to clean their systems within 24 hours. It follows a previous outbreak in July 2015 in the Bronx, which became the second-largest Legionnaires' disease outbreak in the US. Overall, a total of 155 patients were infected and 17 people died due to the disease from July to September that year. The outbreak was eventually linked back to a cooling tower at the Opera House Hotel in the South Bronx, which had been contaminated with the bacteria and was releasing it in water vapor. The largest outbreak was recorded in Philadelphia, Pennsylvania, in 1976, when 221 people were infected and 34 died after breathing in fumes released by the Bellevue-Stratford Hotel's cooling tower.
Reuters
4 hours ago
- Reuters
Pfizer raises 2025 profit forecast as cost-cutting program gains traction
Aug 5 (Reuters) - Pfizer (PFE.N), opens new tab raised its full-year profit forecast on Tuesday while reporting second-quarter results that topped Wall Street estimates, and said it expects to benefit from cost-cutting and a weaker dollar. The New York-based drugmaker said the new forecast absorbs a one-time charge of 20 cents per share related to its licensing deal with China's 3SBio ( opens new tab for an experimental cancer treatment. Pfizer shares rose about 2% to $24 in premarket trading. Pfizer shares have lost more than half their value from their pandemic-era highs as it deals with waning revenue from COVID products and looming patent expirations for key drugs. In response, the company launched cost-saving measures last year across its manufacturing and research operations. Pfizer said it was on track to deliver $7.2 billion in net savings from the programs by the end of 2027, about $4.5 billion coming by the end of 2025. J.P. Morgan analyst Chris Schott said that the quarterly beat and the forecast raise did not come as a surprise given the company's better-than-expected cost management. "We would not be surprised with additional upside to EPS as the year progresses," Schott said. The company now expects adjusted earnings of $2.90 to $3.10 per share, up from its prior view of $2.80 to $3.00. The pharmaceutical industry is facing intense pressure from U.S. President Donald Trump to lower prices Americans pay for prescription medicines, while preparing for 15% tariffs on imports from the European Union. Pfizer shares have fallen over 11% this year, compared to a 1.7% decline for the broader NYSE Arca Pharmaceutical Index (.DRG), opens new tab. The company said its forecast also absorbs the impact of the currently imposed tariffs on goods imported from China, Canada and Mexico, as well as potential price changes this year based on the letter it received from Trump on July 31. "We continue to be actively engaged with policymakers as we navigate a complicated and rapidly evolving geopolitical environment," said CEO Albert Bourla in prepared remarks. Pfizer has said it has enough manufacturing capacity across its 10 U.S. sites to mitigate any tariff impact and is open to shifting some production to those facilities. Total quarterly sales of $14.65 billion topped analysts' estimates by over $1 billion, according to LSEG data, and included a $22 million favorable impact from foreign exchange. Sales of antiviral COVID-19 treatment Paxlovid of $427 million for the quarter far exceeded analysts' expectations of $244.4 million. COVID vaccine Comirnaty, which Pfizer makes with German partner BioNTech ( opens new tab, brought in sales of $381 million. Analysts were expecting $188 million. Quarterly sales of the heart disease treatment sold under brand names Vyndaqel and Vyndamax were $1.62 billion, slightly above estimates of $1.59 billion. Revenue from blood thinner Eliquis, which Pfizer shares with Bristol Myers Squibb (BMY.N), opens new tab, was $2 billion, while analysts were expecting $1.94 billion. On an adjusted basis, Pfizer earned 78 cents per share for the second quarter, topping analysts' expectations by 20 cents.
